Stockscreener 앱 받기
8.37
1.27%
0.13
전일 마감가:
$8.24
열려 있는:
$8.311
하루 거래량:
108.01K
Relative Volume:
0.09
시가총액:
$1.16B
수익:
$175.51M
순이익/손실:
$-78.02M
주가수익비율:
-15.79
EPS:
-0.53
순현금흐름:
$-34.18M
1주 성능:
+0.18%
1개월 성능:
+16.39%
6개월 성능:
+49.28%
1년 성능:
-4.52%
1일 변동 폭
$8.30
$8.405
1주일 범위
$7.87
$8.405
52주 변동 폭
$4.71
$9.74
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
명칭
Aurinia Pharmaceuticals Inc
전화
250-744-2487
주소
#140, 14315 - 118 AVENUE, EDMONTON, BC
AUPH을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| AUPH | 8.35 | 1.16B | 175.51M | -78.02M | -34.18M | -0.53 |
| VRTX | 447.65 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 741.99 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 588.27 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.68 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.49 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-11-04 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-05-05 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-12-10 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-10-28 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-01-25 | 재확인 | H.C. Wainwright | Buy |
| 2020-11-03 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-17 | 개시 | BTIG Research | Buy |
| 2020-05-05 | 개시 | Cowen | Outperform |
| 2020-01-10 | 개시 | Jefferies | Buy |
| 2019-12-16 | 재확인 | H.C. Wainwright | Buy |
| 2018-03-16 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-02-08 | 개시 | RBC Capital Mkts | Outperform |
| 2017-10-30 | 재확인 | H.C. Wainwright | Buy |
| 2017-05-18 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-03-22 | 재확인 | FBR & Co. | Outperform |
| 2016-12-30 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-17 | 재확인 | H.C. Wainwright | Buy |
| 2016-06-30 | 개시 | H.C. Wainwright | Buy |
| 2015-05-08 | 개시 | MLV & Co | Buy |
모두보기
Aurinia Pharmaceuticals Inc 주식(AUPH)의 최신 뉴스
Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis - Business Wire
Layoff Tracker: Gilead Sciences Will Lay Off 104 Employees at California HQ - BioSpace
(AUPH) Technical Pivots with Risk Controls - Stock Traders Daily
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Position Reduced by GSA Capital Partners LLP - MarketBeat
Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024 - sharewise
ARMISTICE CAPITAL, LLC's Strategic Reduction in Aurinia Pharmace - GuruFocus.com
Aurinia to Participate in Jefferies London Healthcare Conference - sharewise
Aurinia Pharmaceuticals Engages at London Conference - TipRanks
Aurinia Pharmaceuticals director Karen Smith sells $44,181 in stock - Investing.com India
Aurinia Pharmaceuticals director sells shares valued at $38,415 - Investing.com India
Aurinia Pharmaceuticals director sells shares valued at $38,415 By Investing.com - Investing.com Canada
Aurinia Pharmaceuticals director Karen Smith sells $44,181 in stock By Investing.com - Investing.com UK
Aurinia Pharmaceuticals (NASDAQ:AUPH) Upgraded at StockNews.com - Defense World
Aurinia Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Aurinia stock jumps 14% on Q3 earnings, restructuring announcement - MSN
Aurinia offers slimmer profile after investor pressure - The Pharma Letter
Leerink Partnrs Issues Optimistic Estimate for AUPH Earnings - MarketBeat
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q3 2024 Earnings Call Transcript - Insider Monkey
Aurinia Pharmaceuticals: A Potential Buyout Looms On The Horizon (NASDAQ:AUPH) - Seeking Alpha
Aurinia slashes workforce by 45% to focus on lupus and autoimmune assets - Pharmaceutical Technology
Earnings call: Aurinia Pharmaceuticals announced a 24% increase in total net revenue - Investing.com
Aurinia Pharmaceuticals Inc (AUPH) Quarterly 10-Q Report - Quartz
Aurinia Pharmaceuticals Announces Restructuring - citybiz
Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Price Up 11%Should You Buy? - MarketBeat
Aurinia: Q3 Earnings Snapshot - The Washington Post
Aurinia stock jumps 14% on Q3 earnings, restructuring announcement (NASDAQ:AUPH) - Seeking Alpha
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development - sharewise
Aurinia Pharmaceuticals (AUPH) Q3 Earnings and Revenues Beat Estimates - Yahoo Finance
Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors - citybiz
Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth - Business Wire
Long Term Trading Analysis for (AUPH) - Stock Traders Daily
Shareholders in Aurinia Pharmaceuticals (NASDAQ:AUPH) are in the red if they invested three years ago - Yahoo Finance
Aurinia Pharmaceuticals (AUPH) to Release Earnings on Thursday - MarketBeat
Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024 - The Bakersfield Californian
Axonis Therapeutics Announces $115 Million Series A Financing - Quantisnow
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) surges 5.9%; individual investors who own 51% shares profited along with institutions - Simply Wall St
Objective long/short (AUPH) Report - Stock Traders Daily
Oppenheimer Downgrades Aurinia Pharmaceuticals Inc (AUPH) to a Perform from an Outperform - Knox Daily
Adversity is less terrifying than hope: Aurinia Pharmaceuticals Inc (AUPH) - SETE News
AQR Capital Management LLC Takes Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World
AQR Capital Management LLC Buys Shares of 202,241 Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat
Aurinia Pharmaceuticals spotlights lupus nephritis drug - Investing.com India
Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024 - BioSpace
Charting the Course: Aurinia Pharmaceuticals Inc’s AUPH Stock Prospects - The InvestChronicle
Aurinia Pharmaceuticals Inc (AUPH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Aurinia Pharmaceuticals Inc 주식 (AUPH) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Smith Karen L. | Director |
Nov 11 '24 |
Sale |
8.43 |
5,241 |
44,182 |
12,672 |
| Habig Scott Michael | Chief Commercial Officer |
Aug 06 '24 |
Sale |
5.31 |
18,249 |
96,902 |
456,338 |
| Balakrishnan Brinda | Director |
May 21 '24 |
Sale |
5.74 |
520 |
2,985 |
17,523 |
| Billen Daniel | Director |
May 21 '24 |
Sale |
5.74 |
5,252 |
30,146 |
28,141 |
| Jayne David R.W. | Director |
May 21 '24 |
Sale |
5.74 |
4,946 |
28,390 |
44,364 |
| Leversage Jill | Director |
May 21 '24 |
Sale |
5.74 |
5,610 |
32,201 |
12,918 |
| MacKay-Dunn R. Hector | Director |
May 21 '24 |
Sale |
5.74 |
5,630 |
32,316 |
18,595 |
| Greenleaf Peter | Chief Executive Officer |
Mar 06 '24 |
Sale |
5.60 |
126,981 |
711,094 |
1,522,114 |
| Miller Joseph M | Chief Financial Officer |
Mar 06 '24 |
Sale |
5.60 |
34,811 |
194,942 |
495,928 |
| Donley Matthew Maxwell | EVP, Ops & Strategy |
Mar 06 '24 |
Sale |
5.51 |
40,665 |
224,064 |
584,072 |
0.42%
0.16%
자본화:
|
볼륨(24시간):